James Crowe Jr.

September 18, 2014

Initiative seeks to develop therapies to combat Ebola

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.

By Bill Snyder
May 1, 2014

Cutting-edge research to be showcased in May

By Bill Snyder
April 7, 2014

Vanderbilt Vaccine Center joins global task force to address urgent viral threat

By John Howser
syringe
March 6, 2014

Multi-center effort targets lethal Ebola, Marburg viruses

Vanderbilt University researchers are collaborating in a multi-center, federally-funded project to develop ways to treat and prevent the highly lethal Ebola and Marburg virus infections.

By Bill Snyder
February 5, 2014

Discovery may pave way for RSV vaccine

Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

By Bill Snyder
January 24, 2014

Nine faculty honored with endowed chairs

Nine Vanderbilt University faculty members named to endowed chairs were honored for their academic achievements during a celebration Jan. 22 at the Student Life Center.

By Bill Snyder
August 22, 2013

Vaccine researchers ready as new flu strain evolves

A worrisome new avian influenza virus, called H7N9, emerged this spring in Eastern China.
By VUMC News and Communications
July 18, 2013

VU researchers ‘goldsmith’ new RSV vaccine approach

Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.
By VUMC News and Communications
February 21, 2013

Structural snapshot hints at new influenza approach

A careful look at how the body’s natural defenses disarm virulent strains of influenza hints at the possibility of a way to fight the flu.
By VUMC News and Communications
April 12, 2012

Targeting post-transplant diabetes

Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.
By VUMC News and Communications
February 15, 2012

On the tail of RSV infection mechanism

New details about the life cycle of respiratory syncytial virus (RSV) could aid the development of therapies to combat this leading cause of serious illness in infants and the elderly.
By VUMC News and Communications
October 7, 2011

Diversity key in antibody repertoire

Antibodies to the 2009 H1N1 influenza strain reveal new insights into how antibody diversity forms and functions, with possible implications for designing flu vaccines.
By VUMC News and Communications
January 6, 2011

Aliquots – VUMC research highlights

By VUMC News and Communications
1 … 6 7 8 9